Bioactivity and Pharmacodynamics of X002, a Follicle-stimulating Hormone-IgG4 Fc Fusion Protein
Comp Med. 2023 Apr 1;73(2):145-52. doi: 10.30802/AALAS-CM-22-000001. Online ahead of print.ABSTRACTCurrent follicle-stimulating hormone (FSH) drugs meet safety criteria but have suboptimal efficacy, poor patient compliance, and high cost. Alternative FSH-like drugs would help to meet the high market demand. Here, we evaluated X002, an FSH-Fc fusion protein, for bioactivity and half-life in vitro and in vivo. In all cases, the effects of X002 were compared with those of a commercially available short-acting FSH recombinant hormone. First, female Kunming mice (age, 21 to 24 d) were stimulated with pregnant mare serum gonadot...
Source: Comparative Medicine - April 18, 2023 Category: Zoology Authors: Guili Xu Yi Yang Yunhui Liu Fang Chen Lihou Dong Deyou Wan Hongjie Li Cuima Yang Xin Gao Source Type: research

Bioactivity and Pharmacodynamics of X002, a Follicle-stimulating Hormone-IgG4 Fc Fusion Protein
Comp Med. 2023 Apr 1. doi: 10.30802/AALAS-CM-22-000001. Online ahead of print.ABSTRACTCurrent follicle-stimulating hormone (FSH) drugs meet safety criteria but have suboptimal efficacy, poor patient compliance, and high cost. Alternative FSH-like drugs would help to meet the high market demand. Here, we evaluated X002, an FSH-Fc fusion protein, for bioactivity and half-life in vitro and in vivo. In all cases, the effects of X002 were compared with those of a commercially available short-acting FSH recombinant hormone. First, female Kunming mice (age, 21 to 24 d) were stimulated with pregnant mare serum gonadotropin (PMSG) ...
Source: Comparative Medicine - April 18, 2023 Category: Zoology Authors: Guili Xu Yi Yang Yunhui Liu Fang Chen Lihou Dong Deyou Wan Hongjie Li Cuima Yang Xin Gao Source Type: research

Bioactivity and Pharmacodynamics of X002, a Follicle-stimulating Hormone-IgG4 Fc Fusion Protein
Comp Med. 2023 Apr 1. doi: 10.30802/AALAS-CM-22-000001. Online ahead of print.ABSTRACTCurrent follicle-stimulating hormone (FSH) drugs meet safety criteria but have suboptimal efficacy, poor patient compliance, and high cost. Alternative FSH-like drugs would help to meet the high market demand. Here, we evaluated X002, an FSH-Fc fusion protein, for bioactivity and half-life in vitro and in vivo. In all cases, the effects of X002 were compared with those of a commercially available short-acting FSH recombinant hormone. First, female Kunming mice (age, 21 to 24 d) were stimulated with pregnant mare serum gonadotropin (PMSG) ...
Source: Comparative Medicine - April 18, 2023 Category: Zoology Authors: Guili Xu Yi Yang Yunhui Liu Fang Chen Lihou Dong Deyou Wan Hongjie Li Cuima Yang Xin Gao Source Type: research

Bioactivity and Pharmacodynamics of X002, a Follicle-stimulating Hormone-IgG4 Fc Fusion Protein
Comp Med. 2023 Apr 1. doi: 10.30802/AALAS-CM-22-000001. Online ahead of print.ABSTRACTCurrent follicle-stimulating hormone (FSH) drugs meet safety criteria but have suboptimal efficacy, poor patient compliance, and high cost. Alternative FSH-like drugs would help to meet the high market demand. Here, we evaluated X002, an FSH-Fc fusion protein, for bioactivity and half-life in vitro and in vivo. In all cases, the effects of X002 were compared with those of a commercially available short-acting FSH recombinant hormone. First, female Kunming mice (age, 21 to 24 d) were stimulated with pregnant mare serum gonadotropin (PMSG) ...
Source: Comparative Medicine - April 18, 2023 Category: Zoology Authors: Guili Xu Yi Yang Yunhui Liu Fang Chen Lihou Dong Deyou Wan Hongjie Li Cuima Yang Xin Gao Source Type: research

Bioactivity and Pharmacodynamics of X002, a Follicle-stimulating Hormone-IgG4 Fc Fusion Protein
Comp Med. 2023 Apr 1. doi: 10.30802/AALAS-CM-22-000001. Online ahead of print.ABSTRACTCurrent follicle-stimulating hormone (FSH) drugs meet safety criteria but have suboptimal efficacy, poor patient compliance, and high cost. Alternative FSH-like drugs would help to meet the high market demand. Here, we evaluated X002, an FSH-Fc fusion protein, for bioactivity and half-life in vitro and in vivo. In all cases, the effects of X002 were compared with those of a commercially available short-acting FSH recombinant hormone. First, female Kunming mice (age, 21 to 24 d) were stimulated with pregnant mare serum gonadotropin (PMSG) ...
Source: Comparative Medicine - April 18, 2023 Category: Zoology Authors: Guili Xu Yi Yang Yunhui Liu Fang Chen Lihou Dong Deyou Wan Hongjie Li Cuima Yang Xin Gao Source Type: research

Bioactivity and Pharmacodynamics of X002, a Follicle-stimulating Hormone-IgG4 Fc Fusion Protein
Comp Med. 2023 Apr 1. doi: 10.30802/AALAS-CM-22-000001. Online ahead of print.ABSTRACTCurrent follicle-stimulating hormone (FSH) drugs meet safety criteria but have suboptimal efficacy, poor patient compliance, and high cost. Alternative FSH-like drugs would help to meet the high market demand. Here, we evaluated X002, an FSH-Fc fusion protein, for bioactivity and half-life in vitro and in vivo. In all cases, the effects of X002 were compared with those of a commercially available short-acting FSH recombinant hormone. First, female Kunming mice (age, 21 to 24 d) were stimulated with pregnant mare serum gonadotropin (PMSG) ...
Source: Comparative Medicine - April 18, 2023 Category: Zoology Authors: Guili Xu Yi Yang Yunhui Liu Fang Chen Lihou Dong Deyou Wan Hongjie Li Cuima Yang Xin Gao Source Type: research

Bioactivity and Pharmacodynamics of X002, a Follicle-stimulating Hormone-IgG4 Fc Fusion Protein
Comp Med. 2023 Apr 1. doi: 10.30802/AALAS-CM-22-000001. Online ahead of print.ABSTRACTCurrent follicle-stimulating hormone (FSH) drugs meet safety criteria but have suboptimal efficacy, poor patient compliance, and high cost. Alternative FSH-like drugs would help to meet the high market demand. Here, we evaluated X002, an FSH-Fc fusion protein, for bioactivity and half-life in vitro and in vivo. In all cases, the effects of X002 were compared with those of a commercially available short-acting FSH recombinant hormone. First, female Kunming mice (age, 21 to 24 d) were stimulated with pregnant mare serum gonadotropin (PMSG) ...
Source: Comparative Medicine - April 18, 2023 Category: Zoology Authors: Guili Xu Yi Yang Yunhui Liu Fang Chen Lihou Dong Deyou Wan Hongjie Li Cuima Yang Xin Gao Source Type: research

Bioactivity and Pharmacodynamics of X002, a Follicle-stimulating Hormone-IgG4 Fc Fusion Protein
Comp Med. 2023 Apr 1. doi: 10.30802/AALAS-CM-22-000001. Online ahead of print.ABSTRACTCurrent follicle-stimulating hormone (FSH) drugs meet safety criteria but have suboptimal efficacy, poor patient compliance, and high cost. Alternative FSH-like drugs would help to meet the high market demand. Here, we evaluated X002, an FSH-Fc fusion protein, for bioactivity and half-life in vitro and in vivo. In all cases, the effects of X002 were compared with those of a commercially available short-acting FSH recombinant hormone. First, female Kunming mice (age, 21 to 24 d) were stimulated with pregnant mare serum gonadotropin (PMSG) ...
Source: Comparative Medicine - April 18, 2023 Category: Zoology Authors: Guili Xu Yi Yang Yunhui Liu Fang Chen Lihou Dong Deyou Wan Hongjie Li Cuima Yang Xin Gao Source Type: research

Bioactivity and Pharmacodynamics of X002, a Follicle-stimulating Hormone-IgG4 Fc Fusion Protein
Comp Med. 2023 Apr 1. doi: 10.30802/AALAS-CM-22-000001. Online ahead of print.ABSTRACTCurrent follicle-stimulating hormone (FSH) drugs meet safety criteria but have suboptimal efficacy, poor patient compliance, and high cost. Alternative FSH-like drugs would help to meet the high market demand. Here, we evaluated X002, an FSH-Fc fusion protein, for bioactivity and half-life in vitro and in vivo. In all cases, the effects of X002 were compared with those of a commercially available short-acting FSH recombinant hormone. First, female Kunming mice (age, 21 to 24 d) were stimulated with pregnant mare serum gonadotropin (PMSG) ...
Source: Comparative Medicine - April 18, 2023 Category: Zoology Authors: Guili Xu Yi Yang Yunhui Liu Fang Chen Lihou Dong Deyou Wan Hongjie Li Cuima Yang Xin Gao Source Type: research

Bioactivity and Pharmacodynamics of X002, a Follicle-stimulating Hormone-IgG4 Fc Fusion Protein
Comp Med. 2023 Apr 1. doi: 10.30802/AALAS-CM-22-000001. Online ahead of print.ABSTRACTCurrent follicle-stimulating hormone (FSH) drugs meet safety criteria but have suboptimal efficacy, poor patient compliance, and high cost. Alternative FSH-like drugs would help to meet the high market demand. Here, we evaluated X002, an FSH-Fc fusion protein, for bioactivity and half-life in vitro and in vivo. In all cases, the effects of X002 were compared with those of a commercially available short-acting FSH recombinant hormone. First, female Kunming mice (age, 21 to 24 d) were stimulated with pregnant mare serum gonadotropin (PMSG) ...
Source: Comparative Medicine - April 18, 2023 Category: Zoology Authors: Guili Xu Yi Yang Yunhui Liu Fang Chen Lihou Dong Deyou Wan Hongjie Li Cuima Yang Xin Gao Source Type: research

Bioactivity and Pharmacodynamics of X002, a Follicle-stimulating Hormone-IgG4 Fc Fusion Protein
Comp Med. 2023 Apr 1. doi: 10.30802/AALAS-CM-22-000001. Online ahead of print.ABSTRACTCurrent follicle-stimulating hormone (FSH) drugs meet safety criteria but have suboptimal efficacy, poor patient compliance, and high cost. Alternative FSH-like drugs would help to meet the high market demand. Here, we evaluated X002, an FSH-Fc fusion protein, for bioactivity and half-life in vitro and in vivo. In all cases, the effects of X002 were compared with those of a commercially available short-acting FSH recombinant hormone. First, female Kunming mice (age, 21 to 24 d) were stimulated with pregnant mare serum gonadotropin (PMSG) ...
Source: Comparative Medicine - April 18, 2023 Category: Zoology Authors: Guili Xu Yi Yang Yunhui Liu Fang Chen Lihou Dong Deyou Wan Hongjie Li Cuima Yang Xin Gao Source Type: research

Bioactivity and Pharmacodynamics of X002, a Follicle-stimulating Hormone-IgG4 Fc Fusion Protein
Comp Med. 2023 Apr 1. doi: 10.30802/AALAS-CM-22-000001. Online ahead of print.ABSTRACTCurrent follicle-stimulating hormone (FSH) drugs meet safety criteria but have suboptimal efficacy, poor patient compliance, and high cost. Alternative FSH-like drugs would help to meet the high market demand. Here, we evaluated X002, an FSH-Fc fusion protein, for bioactivity and half-life in vitro and in vivo. In all cases, the effects of X002 were compared with those of a commercially available short-acting FSH recombinant hormone. First, female Kunming mice (age, 21 to 24 d) were stimulated with pregnant mare serum gonadotropin (PMSG) ...
Source: Comparative Medicine - April 18, 2023 Category: Zoology Authors: Guili Xu Yi Yang Yunhui Liu Fang Chen Lihou Dong Deyou Wan Hongjie Li Cuima Yang Xin Gao Source Type: research

Bioactivity and Pharmacodynamics of X002, a Follicle-stimulating Hormone-IgG4 Fc Fusion Protein
Comp Med. 2023 Apr 1. doi: 10.30802/AALAS-CM-22-000001. Online ahead of print.ABSTRACTCurrent follicle-stimulating hormone (FSH) drugs meet safety criteria but have suboptimal efficacy, poor patient compliance, and high cost. Alternative FSH-like drugs would help to meet the high market demand. Here, we evaluated X002, an FSH-Fc fusion protein, for bioactivity and half-life in vitro and in vivo. In all cases, the effects of X002 were compared with those of a commercially available short-acting FSH recombinant hormone. First, female Kunming mice (age, 21 to 24 d) were stimulated with pregnant mare serum gonadotropin (PMSG) ...
Source: Comparative Medicine - April 18, 2023 Category: Zoology Authors: Guili Xu Yi Yang Yunhui Liu Fang Chen Lihou Dong Deyou Wan Hongjie Li Cuima Yang Xin Gao Source Type: research

Effects of Mouse Kidney Parvovirus on Pharmacokinetics of Chemotherapeutics and the Adenine Model of Chronic Kidney Disease
Comp Med. 2023 Mar 27. doi: 10.30802/AALAS-CM-22-000084. Online ahead of print.ABSTRACTMouse kidney parvovirus (MKPV) causes inclusion body nephropathy in severely immunocompromised mice and renal interstitial inflammation in immunocompetent mice. Here we sought to determine the effects of MKPV on pre-clinical murine models that depend on renal function. To assess the effects of MKPV infection on the pharmacokinetics of 2 renally excreted chemotherapeutic agents, methotrexate and lenalidomide, we measured drug concentrations in the blood and urine of MKPV-infected or uninfected immunodeficient NOD.Cg-PrkdcscidIl2rgtm1Wjl/S...
Source: Comparative Medicine - March 27, 2023 Category: Zoology Authors: Amanda C Ritter Rodolfo J Ricart Arbona Robert S Livingston S ├ębastien Monette Neil S Lipman Source Type: research

Effects of Mouse Kidney Parvovirus on Pharmacokinetics of Chemotherapeutics and the Adenine Model of Chronic Kidney Disease
Comp Med. 2023 Mar 27. doi: 10.30802/AALAS-CM-22-000084. Online ahead of print.ABSTRACTMouse kidney parvovirus (MKPV) causes inclusion body nephropathy in severely immunocompromised mice and renal interstitial inflammation in immunocompetent mice. Here we sought to determine the effects of MKPV on pre-clinical murine models that depend on renal function. To assess the effects of MKPV infection on the pharmacokinetics of 2 renally excreted chemotherapeutic agents, methotrexate and lenalidomide, we measured drug concentrations in the blood and urine of MKPV-infected or uninfected immunodeficient NOD.Cg-PrkdcscidIl2rgtm1Wjl/S...
Source: Comparative Medicine - March 27, 2023 Category: Zoology Authors: Amanda C Ritter Rodolfo J Ricart Arbona Robert S Livingston S ├ębastien Monette Neil S Lipman Source Type: research